CL2013003377A1 - Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto. - Google Patents
Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto.Info
- Publication number
- CL2013003377A1 CL2013003377A1 CL2013003377A CL2013003377A CL2013003377A1 CL 2013003377 A1 CL2013003377 A1 CL 2013003377A1 CL 2013003377 A CL2013003377 A CL 2013003377A CL 2013003377 A CL2013003377 A CL 2013003377A CL 2013003377 A1 CL2013003377 A1 CL 2013003377A1
- Authority
- CL
- Chile
- Prior art keywords
- polypeptide
- polypeptide conjugate
- disorder
- treat
- fraction
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 3
- 102000004196 processed proteins & peptides Human genes 0.000 title 3
- 108090000765 processed proteins & peptides Proteins 0.000 title 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489781P | 2011-05-25 | 2011-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003377A1 true CL2013003377A1 (es) | 2014-07-04 |
Family
ID=47217749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003377A CL2013003377A1 (es) | 2011-05-25 | 2013-11-25 | Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140221287A1 (enExample) |
| EP (1) | EP2714067A1 (enExample) |
| JP (1) | JP2014516049A (enExample) |
| KR (1) | KR20140045433A (enExample) |
| CN (1) | CN103826655A (enExample) |
| BR (1) | BR112013030067A2 (enExample) |
| CA (1) | CA2837104A1 (enExample) |
| CL (1) | CL2013003377A1 (enExample) |
| CO (1) | CO6821894A2 (enExample) |
| EA (1) | EA201391763A1 (enExample) |
| IL (1) | IL229449A0 (enExample) |
| MX (1) | MX2013013802A (enExample) |
| PH (1) | PH12013502385A1 (enExample) |
| SG (1) | SG194998A1 (enExample) |
| TN (1) | TN2013000491A1 (enExample) |
| WO (1) | WO2012162542A1 (enExample) |
| ZA (1) | ZA201309679B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| WO2016034604A1 (en) * | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| CN104327162A (zh) * | 2014-09-28 | 2015-02-04 | 苏州普罗达生物科技有限公司 | 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用 |
| BR112017008157A2 (pt) | 2014-10-24 | 2017-12-19 | Bristol Myers Squibb Co | polipeptídeos de fgf-21 modificados e usos dos mesmos |
| US11028137B2 (en) | 2017-02-01 | 2021-06-08 | The Research Foundation For The State University Of New York | Mutant islet amyloid polypeptides with improved solubility and methods for using the same |
| CA3097812A1 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Thioether cyclic peptide amylin receptor modulators |
| CA3106384A1 (en) | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| EP4534553A1 (en) | 2022-05-27 | 2025-04-09 | Hangzhou Sciwind Biosciences Co., Ltd. | Human amylin analog, and derivative and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005021858D1 (de) * | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| ES2632504T3 (es) * | 2007-11-20 | 2017-09-13 | Ambrx, Inc. | Polipéptidos de insulina modificados y sus usos |
-
2012
- 2012-05-24 MX MX2013013802A patent/MX2013013802A/es not_active Application Discontinuation
- 2012-05-24 BR BR112013030067A patent/BR112013030067A2/pt not_active IP Right Cessation
- 2012-05-24 CN CN201280036795.0A patent/CN103826655A/zh active Pending
- 2012-05-24 KR KR1020137033991A patent/KR20140045433A/ko not_active Withdrawn
- 2012-05-24 EA EA201391763A patent/EA201391763A1/ru unknown
- 2012-05-24 SG SG2013084892A patent/SG194998A1/en unknown
- 2012-05-24 CA CA2837104A patent/CA2837104A1/en not_active Abandoned
- 2012-05-24 WO PCT/US2012/039431 patent/WO2012162542A1/en not_active Ceased
- 2012-05-24 JP JP2014512115A patent/JP2014516049A/ja not_active Withdrawn
- 2012-05-24 EP EP12789229.7A patent/EP2714067A1/en not_active Withdrawn
- 2012-05-24 PH PH1/2013/502385A patent/PH12013502385A1/en unknown
- 2012-05-24 US US14/119,574 patent/US20140221287A1/en not_active Abandoned
-
2013
- 2013-11-14 IL IL229449A patent/IL229449A0/en unknown
- 2013-11-22 TN TNP2013000491A patent/TN2013000491A1/fr unknown
- 2013-11-25 CL CL2013003377A patent/CL2013003377A1/es unknown
- 2013-12-19 CO CO13296527A patent/CO6821894A2/es not_active Application Discontinuation
- 2013-12-20 ZA ZA2013/09679A patent/ZA201309679B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391763A1 (ru) | 2014-04-30 |
| ZA201309679B (en) | 2016-10-26 |
| BR112013030067A2 (pt) | 2016-11-29 |
| CA2837104A1 (en) | 2012-11-29 |
| NZ618526A (en) | 2015-09-25 |
| WO2012162542A1 (en) | 2012-11-29 |
| MX2013013802A (es) | 2014-04-25 |
| JP2014516049A (ja) | 2014-07-07 |
| CO6821894A2 (es) | 2013-12-31 |
| SG194998A1 (en) | 2013-12-30 |
| TN2013000491A1 (en) | 2015-03-30 |
| US20140221287A1 (en) | 2014-08-07 |
| EP2714067A1 (en) | 2014-04-09 |
| PH12013502385A1 (en) | 2014-01-13 |
| IL229449A0 (en) | 2014-01-30 |
| CN103826655A (zh) | 2014-05-28 |
| KR20140045433A (ko) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
| CL2013002612A1 (es) | Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno. | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| CL2013003454A1 (es) | Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada. | |
| BR112014003296A2 (pt) | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112014019750A2 (pt) | composto, composlção farmacêutlca, método para aumentar a lnclusão de éxon 7 de smn2 em mrna, método para aumentar a quantidade de proteína smn e método para tratar sma em um indivíduo humano em necessidade | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| MX2018013333A (es) | Composiciones de nucleasas terapeuticas y metodos. | |
| PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
| BR112012028530A2 (pt) | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CR20130406A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112013019732A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| BR112013020809A2 (pt) | composição para uso no tratamento ou prevenção de disturbio ou doença relacionada a uma mucosa | |
| BR112013014546A2 (pt) | dispositivo e método para administração de um dispositivo vascular | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BR112013014522A2 (pt) | anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer |